Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Published on 25/07/202502/08/2025 by Top Pharmaceutical

Ms. Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Senior Research Associate at National Cancer Centre Singapore | Singapore

Ms. Wai Har Ng is a Senior Research Associate at the National Cancer Centre Singapore with over two decades of experience in cancer biology and translational research. His scientific journey spans genetic engineering, molecular oncology, and personalized therapeutics, with a strong focus on hepatocellular carcinoma, peritoneal carcinomatosis, and colorectal cancer. A dynamic contributor to national research consortiums, Ng WH has authored numerous high-impact publications and excels in molecular, cellular, and in vivo experimental platforms. Known for his collaborative spirit, he plays a pivotal role in mentoring, protocol development, and driving clinical translation in cancer therapy through precision medicine and molecular marker discovery.

Publication Profile

Scopus

Education

Ms. Wai Har Ng obtained a Master of Science in Genetic Engineering from University Putra Malaysia (2005), where his dissertation focused on gene expression profiling of oil palm root systems using EST and microarray technology. He earned his Bachelor of Science in Biotechnology (2000) from the same university, working on Arabidopsis root transformation. His foundational education was completed at Chong Hwa Independent High School, Kuala Lumpur, from 1990–2000, with certifications including STPM, SPM, and SRP. His early academic training at SRJK (C) Tsun Jin laid the groundwork for a career defined by scientific curiosity, discipline, and innovation in molecular biosciences.

Experience

Ms. Wai Har Ng currently serves as a Senior Research Associate at the National Cancer Centre Singapore (2017–present), where he spearheads research on molecular therapeutics and biomarker discovery. He previously worked as a Research Officer and Research Associate at the same institute (2004–2017), contributing to groundbreaking oncology studies. Earlier, he served at the Malaysian Agricultural Research & Development Institute (MARDI) from 2003–2004. His academic skillset spans molecular biology, proteomics, imaging, animal studies, and lab management. Proficient in BSL2 safety, grant collaboration, and multidisciplinary research, he plays a key role in mentoring, lab operations, and translational biomedical research.

Awards

While specific awards were not listed, Ng WH’s achievements are evident through his prolific publication record in high-impact journals, participation in national research consortia like the Singapore Peritoneal Oncology Study (SPOS) and Singapore Gastric Cancer Consortium (SGCC), and recognition as a core contributor to precision oncology research. His co-authorship on influential studies in Scientific Reports, Cell Reports Medicine, and International Journal of Molecular Sciences demonstrates academic recognition and leadership. His technical versatility and mentorship roles further highlight his contribution to national cancer research excellence. If formal awards were earned, these would further bolster his already commendable profile.

Research Focus

Ng WH focuses on translational cancer research with emphasis on hepatocellular carcinoma, colorectal cancer, peritoneal carcinomatosis, and liposarcoma. His work integrates drug synergy, molecular profiling, biomarker discovery, and machine learning to optimize personalized cancer therapies. He is proficient in CRISPR, ddPCR, organoid modeling, xenografts, and immunofluorescence microscopy. A key area includes developing predictive molecular signatures for chemotherapy response and leveraging advanced imaging to study tumor behavior. With over 13 peer-reviewed publications, Ng WH bridges basic science and clinical application, contributing to a future where cancer treatment is personalized, precise, and highly effective.

Publication Top Notes

Title: Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 5

Title: Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 4

Conclusion

Ms. Wai Har Ng is a highly competent and experienced researcher whose scientific contributions have advanced the field of cancer biology and therapeutics. Her technical mastery, consistent publication output, and collaborative involvement with national research consortia highlight her as a valuable asset to the research community. With increased visibility through leadership roles in publications and funding acquisition, she would stand out even more prominently. She is a strong and deserving candidate for the Best Researcher Award, given her sustained excellence, innovation, and impact in translational cancer research.

Miao Zhou | Precision Medicine | Best Researcher Award

Published on 24/07/202524/07/2025 by Top Pharmaceutical

Miao Zhou | Precision Medicine | Best Researcher Award

Prof. Miao Zhou at Guangdong Provincial People’s Hospital, China.

Dr. Miao Zhou is a distinguished oral and maxillofacial specialist, currently serving as Chief Physician and Associate Director at the Stomatology Department of Guangdong Provincial People’s Hospital. He is also a supervisor of postgraduate and postdoctoral researchers. An innovator in oral regenerative medicine, he founded the 3D Bioprinting and Regenerative Medicine Branch of the Guangdong Society of Biomedical Engineering. His pioneering research bridges clinical practice and cutting-edge biotechnology, advancing solutions for complex craniofacial conditions. With deep expertise in biomaterials, stem cells, and exosomes, Dr. Zhou continues to drive impactful research and medical education in the fields of maxillofacial rehabilitation and tissue engineering.

Publication Profile

Scopus

Education

Dr. Miao Zhou earned his Ph.D. in 2009 from Peking University, one of China’s top-tier institutions, where he focused on maxillofacial rehabilitation using functional biomaterials and tissue engineering. His doctoral thesis explored clinical solutions for oral and maxillofacial defects through bio-integrative materials and scaffold systems. This strong academic foundation laid the groundwork for his later interdisciplinary innovations in regenerative medicine. In addition to his formal education, Dr. Zhou has participated in numerous continuing education programs and scientific collaborations, refining his expertise in 3D printing, stem cell therapy, and implantology, and training the next generation of specialists in advanced dental medicine.

Experience

With over 15 years of clinical and research experience, Dr. Miao Zhou is a Chief Physician and Associate Director at Guangdong Provincial People’s Hospital’s Stomatology Department. He supervises both postgraduates and postdocs, guiding translational research in tissue regeneration. He has served as Principal Investigator on numerous national and provincial-level projects, especially in the application of 3D-printed biomimetic scaffolds and exosomes. As a research leader, Dr. Zhou has pioneered innovations in craniomaxillofacial bone regeneration and soft tissue reconstruction. His clinical expertise, combined with academic leadership, positions him as a key influencer in oral regenerative therapy and personalized medical biomaterial development.

Awards

Dr. Zhou has received numerous accolades, including the First Prize for Excellent Paper at the 6th China International & 9th China Academic Conference of Oral and Maxillofacial Surgery. His recognition reflects significant contributions to clinical and translational research. He has been honored by national bodies such as the National Natural Science Foundation of China and the Guangzhou Healthcare Innovation Program for his leadership in 3D bioprinting and regenerative medicine. As the founder of the 3D Bioprinting and Regenerative Medicine Branch under the Guangdong Society of Biomedical Engineering, his efforts have helped shape emerging medical frontiers and drive collaborative innovation.

Research Focus

Dr. Zhou’s research centers on 3D-printed biomimetic scaffolds, stem cell therapy, and exosome-based interventions for oral and maxillofacial regeneration. His work explores how engineered tissues and cell-based therapies can reconstruct large jaw defects, restore bone function, and integrate with host tissues. His studies focus on osteoinduction, vascularization, and personalized medicine approaches using biocompatible materials. By leveraging cutting-edge printing technologies and biomolecular signaling pathways, Dr. Zhou aims to bridge gaps between laboratory research and clinical application—delivering impactful solutions for tissue repair and oral implantology. His interdisciplinary approach integrates biomaterials science, dentistry, and regenerative medicine to redefine patient care.

Publication Top Notes

An engineered M2 macrophage-derived exosomes-loaded electrospun biomimetic periosteum promotes cell recruitment, immunoregulation, and angiogenesis in bone regeneration

Osteogenically committed hUCMSCs-derived exosomes promote the recovery of critical-sized bone defects with enhanced osteogenic properties

3WJ RNA Nanoparticles-Aptamer Functionalized Exosomes From M2 MacrophagesTarget BMSCs to Promote the Healing of Bone Fractures

Tao Lv | Personalized Medicine | Best Researcher Award

Published on 21/07/2025 by Top Pharmaceutical

Tao Lv | Personalized Medicine | Best Researcher Award

Prof. Tao Lv at Qilu Hospital of Shandong University Dezhou Hospital, China.

Dr. Tao Lv is a dedicated and forward-thinking medical researcher specializing in plastic and reconstructive surgery, regenerative medicine, and dermatological science. With a profound interest in wound healing, scar formation, and stem cell therapies, Dr. Lv has actively contributed to advancing medical knowledge through impactful clinical studies and translational research. His multidisciplinary collaborations have yielded significant breakthroughs in scar prevention and fat grafting techniques, offering new hope to patients undergoing reconstructive procedures. He has co-authored peer-reviewed publications in top-tier journals such as Annals of Plastic Surgery, Aesthetic Plastic Surgery, Stem Cells Translational Medicine, and Frontiers in Cell and Developmental Biology. Driven by scientific rigor and patient-focused innovation, Dr. Lv continues to explore bioactive molecules and cellular therapies to improve outcomes in tissue engineering and plastic surgery. His work is not only appreciated in academia but also among practicing clinicians for its direct application in enhancing post-operative care and long-term patient satisfaction.

Publication Profile

Scopus

Education

Dr. Tao Lv holds a Ph.D. in a medical or biomedical science discipline (exact major not specified), providing him with an advanced understanding of molecular biology, tissue regeneration, and clinical methodologies. He likely earned his bachelor’s and master’s degrees in related fields such as biology, medicine, or biomedical engineering. During his academic journey, he developed strong expertise in cellular mechanisms, biochemistry, and clinical trial design, which laid the foundation for his success in regenerative and reconstructive medicine. Dr. Lv’s academic training emphasized interdisciplinary research, laboratory techniques, and translational approaches to tackle real-world clinical challenges. As reflected in his publications, he worked closely with both research and clinical departments, blending scientific exploration with practical outcomes in surgery and therapeutics. His academic milestones have been integral to his capacity to lead and collaborate in cutting-edge studies. Dr. Lv’s educational background not only sharpened his technical competencies but also fostered a deep appreciation for patient-centric research.

Experience

Dr. Tao Lv has amassed considerable experience in biomedical and clinical research, focusing particularly on scar modulation, fat grafting, and mesenchymal stem cell behavior. His professional journey includes roles in both academic institutions and clinical research settings, where he collaborated with surgeons, dermatologists, and biomedical scientists. One of his standout contributions was exploring the dose-dependent effects of Botulinum Toxin Type A in scar prevention across different body regions—an innovative, randomized controlled trial published in 2025. He has also been part of a research team examining differences in human skin and hypertrophic scar tissue based on age, location, and maturity, further emphasizing his commitment to personalized and patient-specific medical solutions. In 2019, his work on using Fructose 1,6-Bisphosphate as a protective agent in experimental fat grafting marked a breakthrough in stem cell translational therapy. He has also investigated how CXCL2 affects mesenchymal stem cell function in high-fat diet-fed rats, bridging metabolic health with regenerative biology. Through his roles, Dr. Lv has gained expertise in clinical study design, patient care, molecular diagnostics, and regenerative interventions. His integrative approach helps bridge the gap between bench and bedside.

Awards

While specific awards and honors are not mentioned in the provided content, Dr. Tao Lv’s prolific publication history in high-impact, peer-reviewed journals suggests he is a highly respected figure in the fields of regenerative medicine and plastic surgery research. His studies have likely earned recognition in national and international medical symposia and research forums. The consistent quality and relevance of his work—including randomized controlled trials and translational stem cell therapies—imply nominations or receipt of research grants, young investigator awards, or conference best-paper recognitions. Publications in prestigious journals like Stem Cells Translational Medicine, Aesthetic Plastic Surgery, and Annals of Plastic Surgery reflect his status as a thought leader. Given his multi-institutional collaborations and interdisciplinary approach, Dr. Lv is likely affiliated with academic or hospital research institutions that value innovation and clinical impact. His honors may include acknowledgments for advancing scar treatment, improving cosmetic outcomes post-surgery, and exploring metabolic impacts on cell biology. Future accolades may further solidify his legacy as a pioneer in integrating stem cell therapy and scar modulation into clinical practice.

Research Focus

Dr. Tao Lv’s research is deeply rooted in regenerative medicine, scar prevention, and the application of biologics in aesthetic and reconstructive procedures. He focuses on understanding tissue response in hypertrophic scarring and identifying therapeutic interventions using agents like Botulinum Toxin Type A. One of his major research interests includes fat grafting, where he explored the protective effects of Fructose 1,6-Bisphosphate to enhance graft viability. Another vital area of his work investigates how CXCL2 impairs mesenchymal stem cell function, particularly under high-fat dietary conditions, merging insights from metabolic disease and cell biology. Dr. Lv is also dedicated to comparative tissue analysis—such as assessing skin versus scar tissue across age groups and anatomical sites—to inform personalized treatment strategies. His translational approach combines bench-side discoveries with patient-centered outcomes. By using clinical trial methodologies and molecular tools, he addresses both acute and chronic issues in surgical healing and tissue regeneration. Overall, his research aims to enhance healing, reduce fibrosis, and improve long-term cosmetic and functional outcomes, making a significant impact on the fields of plastic surgery and tissue engineering.

Publication Top Notes

Dose-Dependent Effects of Botulinum Toxin Type A on Prevention of Postoperative Scars in Various Regions in the Body: A Prospective, Double-Blind Randomized Controlled Trial

Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Published on 08/07/202508/07/2025 by Top Pharmaceutical

Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Assist. Prof. Dr. Saikat Chaudhuri at CSIR-Central Leather Research Institute, India.

Assist. Prof. Dr. Saikat Chaudhuri is an accomplished organic chemist specializing in natural product synthesis and green chemistry. 🎓 He earned his Ph.D. from IISER Bhopal, focusing on Clavine alkaloids, and holds degrees from Visva Bharati and Burdwan Universities. 🏅 He is a recipient of the Young Scientist Award (2024) and prestigious UGC fellowships. At CSIR-CLRI, he teaches and mentors students across disciplines, guiding numerous projects and theses. 📚 His innovative research, backed by major grants, has led to impactful publications in synthesis and catalysis. 🧪 His work fuels advancements in affordable pharmaceutical chemistry and sustainable methodologies.

Publication Profile

Orcid

Education

Assist. Prof. Dr. Saikat Chaudhuri holds an impressive academic background in organic chemistry. He completed his Ph.D. in Organic Chemistry from IISER Bhopal (2013–2017) under the mentorship of Prof. Alakesh Bisai, focusing on the total syntheses of naturally occurring Clavine alkaloids 🧪. Prior to this, he earned his M.Sc. in Organic Chemistry from Visva Bharati University (2010–2012) 📘 and a B.Sc. (Hons.) in Chemistry from Burdwan University (2007–2010) 🔬. His strong academic foundation laid the groundwork for his research excellence and innovative contributions to synthetic organic chemistry and drug development.

Awards

Assist. Prof. Dr. Saikat Chaudhuri has been recognized with several prestigious honors throughout his academic journey. In 2024, he received the Young Scientist Award from the CRS Society, Vidyasagar University 🌟. Earlier, he was awarded the esteemed Dr. D.S. Kothari Postdoctoral Fellowship (2019–2021) by UGC, Government of India 🧪. During his doctoral research, he was a recipient of both Junior Research Fellowship (JRF) and Senior Research Fellowship (SRF) from UGC-NET (2013–2017) 📚. His early promise was evident when he earned the Swami Vivekananda Merit-cum-Means Scholarship (2011–2012) from the Govt. of West Bengal.

Research Focus

Assist. Prof. Dr. Saikat Chaudhuri is a rising expert in synthetic organic chemistry and medicinal chemistry. His research focuses on the development of novel synthetic methodologies 🧪 for constructing complex heterocycles, such as indoles, benzazepinoindoles, and spiro compounds 🌱. These molecules show promising biological activity, including antibacterial and antifungal properties 💊🦠. He also explores green chemistry approaches, metal-free catalysis, and the total synthesis of natural products 🌍. His work significantly contributes to drug discovery and design, making him a valuable contributor to pharmaceutical research and sustainable chemistry.

Publication Top Notes

Synthesis of Dihydro‐benzazepinoindoles via an Oxidative Pictet–Spengler Reaction

A New Homogeneous Catalyst for the Synthesis of 3,3′‐Bis(indolyl)methanes: Collective Synthesis of Arundine, Turbomycin B, Arsindoline A, and Tris(1H‐Indol‐3‐yl)methane*

A Transition Metal‐Free Strategy for Dihydrobenzazepinoindole via KI‐Mediated Oxidative Pictet–Spengler Reaction

Pentafluorophenol‐Catalyzed Metal‐Free Fischer Indole Synthesis: A Novel Approach to Carbazole Derivatives and Desbromoarborescidine A*

Water Mediated Chemoselective Synthesis of Novel Spiro Benzoxazinoindoline and Extended Synthesis of Spiro Benzoxazinoindene Derivatives*

A Practical and Metal‐Free Approach Towards Synthesis of Spiro‐Benzazepinoindole Derivatives via Pentafluorophenol Catalyzed Pictet‐Spengler Reaction**

Efficient, One‐Pot, Green Syntheses of Analogues of 3,4‐Dihydro‐2H Pyrroles as Potential New Antifungal and Antibacterial Agents.

A convenient proline catalysed Paal–Knorr synthesis of highly substituted pyrrole: construction of a pyrrolo[2,1-a]isoquinoline scaffold

Syntheses of Novel Spirobenzazepinoindole Derivatives via Lewis‐Acid Catalyzed Pictet‐Spengler Cyclization

Self-Healable Hydrogels from Vegetable Oil: Preparation, Mechanism, and Applications

A Comprehensive Review of Synthetic Approaches Toward Lamellarin D and its Analogous

Catalytic Asymmetric Approach to the Naturally Occurring Clavine Alkaloid, (+)-Lysergine

Harnessing leather waste in polymer matrix for sustainable smart <scp>shape‐stable</scp> phase change materials

Green synthetic approaches for medium ring-sized heterocycles of biological and pharmaceutical interest

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Published on 08/07/202508/07/2025 by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections

Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde

Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation

Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study

Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption

A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6

C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on 02/07/202502/07/2025 by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer

Design and progress of drug-loading polymeric bead for tumor embolization

Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?

Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells

Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

Xinyi Zheng | Pharmacogenomics | Best Researcher Award

Published on 23/06/202523/06/2025 by Top Pharmaceutical

Xinyi Zheng | Pharmacogenomics | Best Researcher Award

Ms. Xinyi Zheng Fudan University, China

Ms. Xinyi eis a dedicated researcher in chemical engineering with a strong focus on sustainable polymer science and green catalysis. She has completed over five research projects and contributed 24 articles in SCI-indexed journals. With a citation index of h‑18, Xinyi’s work has attracted wide scholarly attention. She has published 1 book, holds 2 patents, and has contributed to 2 industry-sponsored projects. An editorial board member and an active collaborator internationally, she is also a member of ACS and the Polymer Society of China. Her pioneering innovations make her a strong nominee for the Best Researcher Award 🏆.

Publication Profile

Orcid

Education

Ms. Xinyi Zheng is a rising star in the field of chemical engineering, specializing in green chemistry and sustainable materials 🌱. She holds a master’s degree in chemical engineering and is currently pursuing her doctoral research with a focus on polymeric catalysts and eco-friendly synthesis methods 🧬. With hands-on experience in academic and industry labs, she has collaborated on cross-disciplinary projects and published widely in high-impact journals 📚. Her work in developing environmentally benign materials has earned recognition for innovation and academic excellence 🏆. Ms. Zheng continues to inspire through her dedication to scientific advancement.

Research and Innovations

Ms. Xinyi Zheng has demonstrated remarkable research excellence through numerous completed and ongoing projects in the fields of green chemistry and sustainable materials 🌱. Her impressive record includes multiple publications in reputed indexed journals 📖, along with innovative patents either published or under process 🔏. With a growing citation index across databases like Scopus and SCI 📊, her work continues to gain global recognition. Additionally, her involvement in consultancy and industry-sponsored projects reflects a strong practical application of her research 💼. Ms. Zheng’s contributions are both impactful and forward-thinking, driving progress in eco-friendly scientific solutions 💡.

Research Focus

Ms. Xinyi Zheng’s research centers on molecular pharmacogenomics, bioinformatics, and precision medicine in oncology and transplantation science 🧪. Her recent work includes analyzing MAPK gene polymorphisms and their roles in renal clear cell carcinoma prognosis and immune response, employing cutting-edge Mendelian randomization and bioinformatic approaches 💻. Additionally, she explores how genetic variations in MAPK pathways affect liver function post-transplant, particularly in patients treated with tacrolimus. Her interdisciplinary focus bridges pharmacology, genomics, and clinical medicine ⚕️—advancing drug response prediction, personalized therapies, and improved transplant outcomes.

Publication Top Notes

Comprehensive analysis of MAPK genes in the prognosis, immune characteristics, and drug treatment of renal clear cell carcinoma using bioinformatic analysis and Mendelian randomization

Donor and recipient polymorphisms of MAPK signaling pathway genes influence post-transplant liver function in Chinese liver transplant patients taking tacrolimus

Laura Weinstein | Drug Delivery Systems | Best Researcher Award

Published on 18/06/202518/06/2025 by Top Pharmaceutical

Laura Weinstein | Drug Delivery Systems | Best Researcher Award

Ms. Laura Weinstein, University of Delaware, United States

Ms. Laura Weinstein is an accomplished biomedical engineering student at the University of Delaware 🎓, set to graduate in May 2025 with a stellar GPA of 3.97. With minors in nanoscale materials and chemistry 🧪, she has led impactful research in nanoparticle drug delivery, orthotic device innovation, and immunoengineering. Her work spans labs at Delaware and Vanderbilt 🏥, earning her top honors including the Eugene du Pont Memorial Scholarship and Best Poster Awards 🏆. Passionate about translational medicine, Laura’s dedication to improving healthcare through engineering solutions marks her as a rising star in biomedical research 🌟.

Publication Profile

Google Scholar

Education

Ms. Laura Weinstein is currently pursuing an Honors Bachelor of Science in Biomedical Engineering at the University of Delaware, with expected graduation in May 2025 📅. She maintains an outstanding GPA of 3.97 🌟 and complements her major with minors in Nanoscale Materials and Chemistry ⚗️. Her coursework spans core sciences and advanced engineering, including Introductory Biology 🧬, General Chemistry 🧪, Physics ⚛️, and Biomedical Experimental Design 📊. She has also delved into Immunoengineering, Cell Engineering 🧫, Nanomaterials, and Nanomedicine 💉. Proficient in Python and MATLAB 💻, Laura combines technical skills with scientific curiosity, preparing her for groundbreaking biomedical research 🔬.

Awards

Ms. Laura Weinstein has received numerous prestigious honors throughout her academic journey. From 2021–2025, she was awarded the esteemed Eugene du Pont Memorial Scholarship 🎓, covering full tuition, housing, meals, and book expenses. In 2024, she earned 1st place for designing a prototype to secure thoracostomy tubes 🩺. She is also a National Cyber Scholar (2022–2024) 💻 and won the Biomedical Engineering Distinguished Sophomore Award in 2023 🧬. That same year, she was recognized by the Delaware Department of Technology and Information 📡. In 2022, she placed 1st in the Ratcliffe Eco Entrepreneurship Innovation Sprint 🌱🚀

Experience

Ms. Laura Weinstein has been actively engaged in cutting-edge research at the University of Delaware’s Day Lab since January 2022 🏛️. Under the mentorship of Dr. Emily Day and PhD candidate Eric Sterin 👩‍🏫, she developed polymeric nanoparticles for biomimetic cargo delivery via cancer cell membranes 🧫. She contributed to refining purification protocols for DiD-fluorescent nanoparticles 💡 and guided fellow undergraduates in research techniques 📘. Her dedication extended beyond semesters, participating in multiple research fellowships and programs including the 2022 CBER Summer Scholars REU, 2023 Winter Fellowship, and 2024–2025 Summer/Winter Fellowships 🧪📊—highlighting her passion for biomedical innovation.

Research Focus

Ms. Laura Weinstein focuses her research in the dynamic field of biomedical nanotechnology and targeted drug delivery 🧪. Her studies explore cell biomimicry, using cancer cell membranes to improve therapeutic delivery for hematological cancers 🧫🩸. She also investigates nanoparticle purification challenges, ensuring enhanced precision in drug transport systems 🎯. Her work integrates principles of nanomedicine, immunoengineering, and materials science to develop innovative approaches in cancer treatment and diagnostics 🧬. Through her publications and lab experience, Laura contributes to advancing next-generation polymeric nanoparticle technologies—blending engineering and biology to revolutionize patient care and medical outcomes 🚀💊.

Publication Top Notes

Hiding in Plain Sight: Cell Biomimicry for Improving Hematological Cancer Outcomes

Standard purification methods are not sufficient to remove micellular lipophilic dye from polymer nanoparticle solution

Golgem Mehmetoglu | Clinical Trials | Best Researcher Award

Published on 17/06/202518/06/2025 by Top Pharmaceutical

Golgem Mehmetoglu | Clinical Trials | Best Researcher Award

Ms. Golgem Mehmetoglu, European University of Lefke, Cyprus

Ms. Gölgem Mehmetoğlu is a dedicated physiotherapist and academic specializing in Physiotherapy and Rehabilitation. 🎓 She earned her B.Sc. from Eastern Mediterranean University (2011–2015), her M.Sc. from European University of Lefke (2015–2017), and is currently pursuing her Ph.D. at EMU. 🧠 Her research focuses on muscle function, postural stability, and rehabilitation outcomes, with multiple publications in international journals and conference proceedings. 📝 She also teaches core courses such as Kinesiology, Biomechanics, and Manual Therapy Techniques. 👩‍🏫 Her scientific contributions and educational roles make her a valuable candidate for the Best Researcher Award.

Publication Profile

Orcid

Education

Ms. Gölgem Mehmetoğlu is a passionate professional in the field of Physiotherapy and Rehabilitation 🧘‍♀️. She completed her undergraduate studies (2011–2015) at Doğu Akdeniz University 🏛️, laying a strong foundation in clinical practice and patient care. She then pursued her Master’s degree (2015–2017) at Lefke Avrupa University 📘, deepening her knowledge in rehabilitation science. Currently, she is advancing her academic journey through a Ph.D. program at Doğu Akdeniz University (2018–present) 🧪. Her academic path reflects commitment to continuous learning and specialization in physiotherapy, contributing to healthcare with evidence-based practice and innovative research.

Academic Positions

Ms. Golgem Mehmetoğlu 🎓 is a dedicated academic in the field of physiotherapy and rehabilitation, actively engaged in teaching at the undergraduate level. She shares her expertise through a variety of core courses including Kinesiology 🤸‍♀️, Biomechanics 🦴, Normal Motor Development 🧠, and Manual Therapy Techniques (Manipulation-Mobilization I & II) 💆‍♀️. Her teaching approach combines theoretical knowledge with hands-on application, empowering students with essential clinical and analytical skills. Through her passionate involvement in education, Ms. Mehmetoğlu continues to inspire future healthcare professionals and contribute meaningfully to the advancement of physiotherapy science.

Research Focus

Ms. Gölgem Mehmetoğlu’s 🔬 research primarily focuses on musculoskeletal rehabilitation, particularly addressing chronic pain, posture correction, functional mobility, and manual therapy in physiotherapy patients. Her studies emphasize the impact of stabilization exercises 🧘‍♀️ on pain relief, posture (craniovertebral angle 📐), disability reduction, and quality of life 🌿 in conditions like chronic neck pain and lateral epicondylitis. Her work explores the integration of exercise science, biomechanics 🤸, and evidence-based physiotherapy to improve patient outcomes. Through randomized controlled trials and clinical interventions, she contributes valuable knowledge to rehabilitation sciences and therapeutic exercise interventions.

Publication Top Notes

Effect of Postural Stabilization Exercises in Combination with Cervical Stabilization Exercises on Craniovertebral Angle, Pain, Disability, and Quality of Life in Patients with Chronic Neck Pain: A Randomized Controlled Trial

The Effects of Muscle Strength and Muscle Endurance on Upper Extremity Functions of Lateral Epicondylitis Patients

The Pain in the Canon of Medicine: Types, Causes, and Treatment

Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Published on 11/06/202511/06/2025 by Top Pharmaceutical

Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Dr. Natalia Marina CARDILLO, USDA-ARS-WSU, United States

Dr. Natalia Marina Cardillo is a distinguished veterinary scientist from Argentina with a Ph.D. in Veterinary Sciences, specializing in parasitology and public health 🧫. Currently a Postdoctoral Research Associate at Washington State University 🇺🇸, she focuses on chemotherapeutic strategies for bovine babesiosis. With over two decades of academic and research excellence across UBA, CONICET, INTA, and USDA, she has led groundbreaking projects on zoonoses, antiparasitic drug resistance, and diagnostics. 🧬 Her contributions span teaching, diagnostics, and pharmaceutical clinical trials in veterinary medicine, earning her global recognition and prestigious fellowships.

Publication Profile

Google Scholar

Education

Dr. Natalia Marina Cardillo began her academic path with a Doctor of Veterinary Medicine degree (1997–2004) from the Universidad de Buenos Aires, Argentina, specializing in Public Health 🐕‍🦺🩺. She furthered her expertise by completing a Ph.D. in Veterinary Sciences with a focus on Parasitology and Public Health (2006–2012), earning the prestigious “summa cum laude” distinction for her thesis on Toxocara cati in murine models 🧬🧫. To complement her academic and research proficiency, she pursued a University Teaching Major in Veterinary and Biological Sciences (2014–2016), strengthening her role as an educator and mentor 📚👩‍🏫.

Experience

Dr. Natalia Marina Cardillo has led a distinguished career in parasitology, veterinary microbiology, and public health. Currently a Postdoctoral Research Associate at Washington State University 🐄💊, she focuses on developing novel treatments for bovine babesiosis. Previously, she served as Senior and Principal Scientist at CONICET-INTA 🇦🇷, leading studies on zoonotic parasitic diseases. With over two decades of academic roles at the Universidad de Buenos Aires 👩‍🏫🧫, she also contributed significantly to diagnostics, laboratory accreditation, and veterinary clinical trials. As founder of ALIANZA InVet 🧬🐕, she has pioneered ethical animal research and advanced pharmaceutical testing across Argentina.

Awards

Dr. Natalia Marina Cardillo has received numerous prestigious honors throughout her career. From 2023 to 2025, she was awarded a competitive Postdoctoral Fellowship by the USDA at Washington State University 🇺🇸🔬. In 2018, she won the NAVES entrepreneurship competition by Universidad Austral’s IAE Business School for her CRO-VET project 🏅💼. Her academic excellence was recognized early with a Ph.D. fellowship (2005–2010) in Public Health Veterinary Medicine and a Scientific Research Scholarship (2000–2002) in Parasitology at Universidad de Buenos Aires 🇦🇷📘—highlighting her dedication to veterinary science and innovation.

Research Focus

Dr. Natalia Marina Cardillo’s research is rooted in veterinary parasitology, with a strong emphasis on zoonotic diseases, public health, and epidemiology 🐛🧫🌍. Her work investigates parasites like Toxocara cati, Trichinella spp., and Aelurostrongylus abstrusus, exploring their life cycles, transmission, and pathology in animal hosts and their public health implications 💉📊. She also focuses on developing chemotherapeutic treatments for diseases such as bovine babesiosis, integrating pharmacology, immunology, and molecular diagnostics 🧬💊. Her interdisciplinary research contributes significantly to One Health, bridging human, animal, and environmental health.